We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNMD icon
126
CONMED
CNMD
$1.53B
$498K 0.03%
+8,554
New +$461K
THC icon
127
Tenet Healthcare
THC
$21.9B
$492K 0.03%
8,500
– –
APYX icon
128
Apyx Medical
APYX
$131M
$482K 0.03%
172,700
-27,300
-14% -$75.1K
INFI
129
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$449K 0.03%
41,000
-20,000
-33% -$257K
JNP
130
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$411K 0.02%
+44,900
New +$339K
AKAO
131
DELISTED
Achaogen Inc
AKAO
$362K 0.02%
60,000
– –
OREX
132
DELISTED
Orexigen Therapeutics, Inc.
OREX
$350K 0.02%
+7,060
New +$422K
KERX
133
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$343K 0.02%
34,380
-50,000
-59% -$536K
PARN
134
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$341K 0.02%
68,800
-127,700
-65% -$563K
SUPN icon
135
Supernus Pharmaceuticals
SUPN
$2.64B
$331K 0.02%
+19,470
New +$277K
CBM
136
DELISTED
Cambrex Corporation
CBM
$322K 0.02%
7,331
– –
XENT
137
DELISTED
Intersect ENT, Inc
XENT
$293K 0.02%
+10,251
New +$269K
SYNH
138
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$291K 0.02%
+7,261
New +$251K
GILD icon
139
Gilead Sciences
GILD
$184B
$288K 0.02%
2,457
-7,543
-75% -$824K
GTS
140
DELISTED
Triple-S Management Corporation
GTS
$272K 0.02%
11,147
– –
UHS icon
141
Universal Health Services
UHS
$10.4B
$268K 0.02%
1,883
-350
-16% -$43.8K
PAHC icon
142
Phibro Animal Health
PAHC
$1.43B
$265K 0.02%
6,809
– –
MRGE
143
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$264K 0.02%
55,015
-27,412
-33% -$131K
CYH icon
144
Community Health Systems
CYH
$419M
$250K 0.02%
+4,813
New +$216K
HNT
145
DELISTED
HEALTH NET INC
HNT
$246K 0.01%
3,831
-278
-7% -$16.6K
LMAT icon
146
LeMaitre Vascular
LMAT
$1.81B
$239K 0.01%
+19,838
New +$195K
ITGR icon
147
Integer Holdings
ITGR
$4.26B
$237K 0.01%
4,817
– –
ELV icon
148
Elevance Health
ELV
$86.5B
$236K 0.01%
+1,436
New +$229K
MCK icon
149
McKesson
MCK
$106B
$228K 0.01%
1,015
– –
LHCG
150
DELISTED
LHC Group LLC
LHCG
$226K 0.01%
5,917
– –
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.